Tarsus Pharmaceuticals (TARS) Change in Accured Expenses (2019 - 2026)

Tarsus Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 574.3% year-over-year to $7.7 million in Q1 2026; TTM through Mar 2026 was $8.5 million, a 67.95% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 94.82% from the prior year.
• Change in Accured Expenses grew to $7.7 million in Q1 2026 per TARS's latest filing, from -$35.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $30.5 million in Q3 2024 and bottomed at -$35.5 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $2.0 million (2022), against an average of $3.3 million.
• Biggest YoY gain for Change in Accured Expenses was 1039.45% in 2024; the steepest drop was 1694.09% in 2024.
• Year by year, Change in Accured Expenses stood at -$473000.0 in 2022, then jumped by 638.9% to $2.5 million in 2023, then surged by 390.51% to $12.5 million in 2024, then sank by 383.84% to -$35.5 million in 2025, then surged by 121.74% to $7.7 million in 2026.
• Per Business Quant, the three latest TARS Change in Accured Expenses figures stand at $7.7 million (Q1 2026), -$35.5 million (Q4 2025), and $23.8 million (Q3 2025).